MGTA-117
Phase 1Biologic
MGTA-117 is one of 9 biologic programs targeting Adult Acute Myeloid Leukemia. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Adult Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaApproved
Revuforj
SSyndax Pharmaceuticals
Approved
Standard Dose ARA-C
NNational Research Center for Hematology, Russia
Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
High Dose Ara-C
PProf. Dr. M. Dreyling (co-chairman)
Approved
Ara-C
KKaryopharm Therapeutics Inc
Phase 2
Venclexta
AbbViePreclinical
Cerubidine
HHikma Pharmaceuticals LLC
Preclinical
MGTA-117
MMagenta Therapeutics, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MGTA-117. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- MMagenta Therapeutics, Inc.